ABSTRACT: Direct-to-consumer (DTC) prescription drug advertisements for HIV antiretrovirals are controversial and have been criticized in the past for including deceptive images and underplaying HIV drug limitations. We sought to describe the state of recent DTC ads for HIV antiretrovirals in popular magazines by performing a content analysis of all complete DTC ads for antiretroviral medications appearing in eight national magazines during a one-year period. Current ads appear to have addressed previous concerns, but important problems still exist, such as failing to specify the medication's role in current treatment, to quantify drug efficacy, or to highlight life-threatening side effects. [Health Affairs 26, no. 5 
D
e s p i t e o p p o s i t i o n , direct-toconsumer (DTC) advertising of prescription drugs continues to thrive in the United States. Banned almost everywhere else in the world, DTC ads were a $4.8 billion enterprise in the United States in 2006 (more than twice the total Food and Drug Administration, or FDA, budget). 1 From the start, these ads have been controversial: Proponents argue that they educate consumers about treatment options, while opponents claim that the ads overstate drug benefits, minimize harms, and lead to inappropriate patient demand. 2 DTC advertising for HIV antiretroviral medications has been especially controversial. In addition to the aforementioned concerns, some in the HIV community worry that such ads might present an overly optimistic picture of HIV treatment, undermining public health efforts to diminish risky behavior and thereby increase the risk of HIV transmission. In fact, one study suggested that these ads reduced the sense that HIV was a serious problem and, in some groups, might have encouraged greater exposure to unprotected sex. 3 In 2001 the FDA issued a letter to all eight companies producing HIV antiretroviral drugs expressing concern that current ads were potentially misleading when they con-tained images that were not representative of people living with AIDS (for example, an ad showing people involved in strenuous athletic activity such as mountain climbing). The letter also stated that the ads often failed to clearly communicate three limitations of the medications: that the drugs do not cure HIV, that they must be taken with other medications active against HIV, and that they do not eliminate the possibility of transmitting HIV to others. 4 To evaluate whether these concerns continue to be a problem, we analyzed the content of recent DTC ads for antiretroviral medications. We also assessed how well the ads communicated other basic information about drug indications, efficacy, and side effects.
Study Data And Methods
n Magazine selection. To identify DTC ads for antiretrovirals, we selected magazines in the following readership categories: male health enthusiasts, homosexual men, and people living with HIV. We searched each category using Ulrich's Periodicals Directory to find national, American, English-language, general-interest magazines (for example, fitness rather than bodybuilding) that included paid advertisements. We required publication of at least ten issues per year and an estimated circulation of at least 50,000 (excluding newsletters and obvious pornography). Eight magazines met our requirements: two for men's health (Men's Fitness and Men's Health), four for homosexual men (Genre, Instinct, Out, and the Advocate), and two for people living with HIV (A&U and Poz). We then reviewed up to twelve issues per magazine from June 2004 to May 2005. We attempted to review one issue per month for magazines published monthly or more frequently (the first issue of the month if more than one issue per month) and all of the issues for magazines published less frequently.
n Ad categories. We identified all ads for HIV antiretrovirals in each magazine issue. An ad was considered unique if either the picture or the text varied from any previous ads. Ads were grouped based on the three FDA-recognized categories for DTC ads and one new category (expanded access): complete ads (that is, drug name, indication, a brief summarysmall-print extract of the FDA-approved label, usually on the back of the ad-and typically an image), reminder ads (drug name mentioned but no indication or dosing), help-seeking ads (disease information provided but no drug named), and expanded-access ads (about a program for obtaining a drug not yet approved). 5 n Content analysis. We evaluated ads according to the following criteria using a standardized coding scheme.
Prior FDA concerns. Did the ads address prior FDA concerns about deceptive images (such as athletic activities) and about failure to state that the drug is not a cure, does not prevent HIV transmission, and must be used in combination with other antiretro-virals?
Indication. Did the ad mention the drug's indications? Were the indications accurate? Indications were categorized as initial preferred agents, initial alternative agents, and agents not recommended for initial treatment (salvage) based on guidelines from a Department of Health and Human Services (HHS) panel. 6 Efficacy. What efficacy measure was reported (for example, viral load or survival), and was it quantified? To learn which drugs have a demonstrated survival benefit, we examined the concurrently approved FDA labeling for all included drugs.
Side effects. Were the important side effects reported, highlighted, and quantified? We compared side effects reported in the ad to the side-effect profile of the advertised medications as reported in the same HHS guideline. We further grouped the guideline side effects into three categories: black-box/life-threatening (FDA black-box warnings and potentially life-threatening side effects such as lactic acidosis), long term (long-term consequences such as insulin resistance), and nuisance (problems the panel judged to be bothersome enough to either limit the quality of life or inhibit medication adherence, such as frequent diarrhea). A side effect was considered highlighted from other side effects if it was bolded, underlined, in a specific text box, or visually set off.
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Other drug information. Did the ad report inconvenience factors (for example, number of pills) or cost?
n Coding. All unique ads were coded by two reviewers: one reviewer who designed the study and one of two reviewers who were blinded to the study's hypothesis. Inter-rater agreement was "almost perfect": Kappas (determined using Stata 9.0) ranged from 0.81 (for efficacy claims) to 1.00 (for characteristics of the image) and averaged 0.91 overa11. 7 Discrepancies between the reviewers for each ad were resolved by consensus.
Study Findings
We identified forty-five unique ads: thirtyeight (84 percent) complete ads, two reminder ads, three help-seeking ads, and two expanded-access ads. The thirty-eight complete ads appeared a total of 190 times in magazines in the homosexual men and HIV/AIDS categories and represented thirteen different antiretroviral drugs (Exhibit 1). Five of the drugs were advertised within one year of the date of their FDA approval.
n Prior FDA concerns. Only one of the thirty-eight complete ads depicted people par- H e a l t h T r a c k i n g SOURCE: Authors' review of content. NOTES: Because we were not able to obtain a few back issues, estimates were based on seven of ten issues (Men's Fitness), seven of ten issues (Genre), and eleven of twelve issues (Out). Complete ads contained both a front page and a brief summary.
ticipating in athletic activities (Exhibit 2). Also, the three statements suggested by the FDA to describe drug limitations were found on the front of almost all of the ads (Exhibit 2). Of note, during the study, the FDA requested the discontinuation of one of these ads (for nevirapine) for failing to adequately display these limitations. 8 n Indication. Six (16 percent) of the ads indicated (on the front page) whether the drug was a first-line or alternative agent (one advertised lopinavir/ritonavir as "initial preferred"; five mentioned that enfurvitide is for "treatment experienced" patients).
n Efficacy (front page). Twenty-four (63 percent) of the thirty-eight ads reported that the drug improved CD4 (T helper cell) counts or reduced viral loads, but only seven (18 percent) quantified the magnitude of these benefits. When claims were quantified, they were typically expressed in relative terms without a base rate (five of seven for viral load claims, five of five for CD4 claims)-a format known to exaggerate the effect. 9 For example, one ad stated that people treated with enfurvitide were "twice as likely to get to undetectable" without saying twice as likely as what.
Eight ads-for five different drugs-made claims that the drug improved survival. Of note, only one of these drugs (zidovudine/ lamivudine) contains a drug (zidovudine) that has a survival benefit as part of its FDAapproved label. In three ads (two for zidovudine/lamivudine and one for nelfinavir), there were explicit survival claims specific either to the drug or to antiretrovirals in general (for example, an ad for nelfinavir stated, "As drugs today help those with HIV live longer…"). The other five ads implied a survival benefit, including one ad for zidovudine/lamivudine. For example, an ad for lopinavir/ritonavir showed a series of pictures of the same person in good health over five years (the FDA requested that this ad be discontinued, believing that these images constituted an unsubstantiated survival claim). 10 n Side effects. Most of the ads provided long lists of side effects: 76 percent listed nine or more; 42 percent had thirteen or more on the front page, while 87 percent had nine or more and 66 percent had thirteen or more in the brief summary. On the front of the ad, only fifteen of the ads (45 percent) with FDA blackbox warnings or life-threatening side effects as described in the HHS guideline, or both, included a complete list of these side effects (the others contained a partial list). 11 These serious side effects were often not highlighted (that is, visually or graphically set off from other less dangerous side effects): 48 percent failed to do so on the front page, and 27 percent failed to do so in the brief summary.
Side effects were also infrequently quantified on the front page: 3 percent for blackbox/life-threatening side effects, 4 percent for long-term side effects, and 63 percent for nuisance side effects. When they were quantified, usually no comparisons were made (for example, "Reyataz in combination therapy had a 1-3% rate of moderate-to-severe diarrhea").
n Other information. Many ads failed to mention drug-related inconveniences: 26 percent failed to describe the number of doses per day; 64 percent did not report how many pills per day the regimen required, 20 percent of the ads for medications that have food restrictions failed to mention this fact, and none of the (four) ads for medications requiring refrigeration mentioned this fact. Cost was not reported in any of the ads.
Discussion
Current DTC ads for HIV antiretrovirals appear to have largely addressed the concerns expressed by the FDA in 2001. This is an encouraging finding and suggests that the FDA's letter of concern may have had an effect. Nonetheless, important problems still exist. The FDA requested that one of the ads (among the thirty-eight unique ads in this study) be discontinued because the images conveyed an unsubstantiated survival claim of efficacy for the drug. Many ads were missing basic facts that consumers need to weigh the relative merits of a drug: how it is used, how well it works, and how often side effects occur.
Although these omissions do not technically violate current FDA regulations, we contend that they do violate the regulations' real intent: to provide true and balanced information on drugs' side effects and effectiveness, to not be misleading, and to support the claims made. The main problem is in how the regulations are written. For example, in describing the scope of information to be included in the brief summary relating to drugs' effectiveness, the regulation only calls for the "specific indications for use of the drug for purposes claimed in the advertisement" but says nothing about describing, let alone quantifying, how well the drug works. 12 Without basic data on drugs' effectiveness, consumers (and physicians) cannot decide if the drug's benefit is big enough to matter. In fact, in the absence of efficacy data, patients viewing drug ads tend to overestimate a drug's benefit. 13 n Limitations. Our study has several limitations. First, we provide only a snapshot of current HIV antiretroviral ads. Consequently, we do not have an estimate of the prevalence of the concerns that the FDA expressed in 2001. Second, content analysis is always a subjective process. We attempted to minimize subjectivity by focusing on the more objective attributes of the ads and having a standardized coding scheme. Our success in this effort is demonstrated by the very high level of interrater agreement achieved. Finally, we did not directly evaluate how these ads affect consumers, physicians, or prescribing decisions.
n Important consequences. Because HIV infection has implications for both personal and public health, DTC ads for antiretrovirals may have especially important consequences. To the extent that the ads appropriately target people at risk for HIV, they may encourage testing and needed treatment and perhaps reduce the stigma of the disease. However, to the extent that the ads present an overly optimistic picture of HIV treatment, they might instill a false sense of security in people both infected with HIV and at risk for infection. A survey conducted in San Francisco supports this concern: Among HIV-positive homosexual men, those with the greatest exposure to ads depicting healthy-appearing men thought that HIV was a less serious disease than did men with less exposure (36 percent versus 6 percent, (p < 0.03). 14 Of note, few of the DTC ads contained any other public health messages (six suggested that medication adherence was important, and five advised seeing a health care provider regularly). No ad mentioned condoms to decrease the risk of transmission-a missed opportunity to disseminate an important educational message.
n General problems in DTC ads. Although some of these problems are specific to HIV antiretrovirals, most reflect general problems inherent in DTC advertising: Drugs' benefits are rarely quantified in DTC ads (and when quantified use formats that exaggerate the size of the effect), and side effects are typically presented in long lists-typically without any prioritization. 15 Concerns that DTC ads overstate benefit and minimize side effects are most relevant with newly approved drugs. Because FDA approval is usually based on short-term (typically forty-eight weeks of evaluation for HIV drugs) and relatively small trials, long-term benefits are often unknown, and infrequent but important side effects might not emerge until the postapproval phase, when thousands of people are exposed (most black-box warnings and drug recalls occur in the first few years after FDA approval). 16 Problems such as lactic acidosis with nucleoside reverse transcriptase inhibitors and glucose intolerance with protease inhibitors, for example, took years to be fully appreciated. 17 Therefore, many have argued for a waiting period to accumulate more experience with drugs before DTC ads are allowed. 18 Almost half of the drugs in our study had at least one advertisement within the first year of FDA approval.
n Policy recommendations. Regardless of the fate of new drug advertising, the FDA has recognized the need to improve the informational content of DTC ads. 19 Although the FDA issued draft voluntary guidance to the pharmaceutical industry about the brief summary, this guidance did not address the need to routinely provide efficacy and side-effect data in a meaningful way. 20 Elsewhere we have suggested a standardized presentation format (a drug facts box) to replace the brief summary and have shown that consumers can understand it. 21 The drug facts box is a one-page summary that includes descriptive information (such as how the drug should be used) and a data table. The table summarizes drugs' benefit and side-effect data from published trials used in the FDA's drug approval process. The table includes two columns of numbers: the chances of various outcomes for people who do or do not take the drug. Side effects would be categorized as either life-threatening or nuisance. And, based on explicit decision rules, the number of side effects presented would be limited to avoid data overload (complete lists would still be available on the FDA or company Web sites).
Avoiding data overload would also prohibit inclusion of all of the informational items we looked for in our content analysis, such as dosing convenience, daily number of pills, and so forth. We believe that many of these items would help consumers understand their treatment options (a chief purpose of DTC ads according to their proponents), but we would encourage but not require their inclusion in ads because these items are not crucial to understanding how a drug performs.
In addition, if the FDA continues to permit DTC advertising of HIV drugs, either a oneyear moratorium on advertising new medications or a "new drug warning" (that is, an alert that many drug side effects emerge only after FDA approval) should be established. And when advertising is permitted, the FDA should require that drug benefits, side effects, and inconvenience be reported in a meaningful way. Finally, the FDA should insist that all ads high-M a r k e t W a t c h light how to minimize the risk of HIV transmission altogether. 
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